Track Aeglea BioTherapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aeglea BioTherapeutics, Inc. AGLE · Stock Open Aeglea BioTherapeutics, Inc. in new tab

12.01 USD
Loading chart...

DCF valuation

Model fair value for Aeglea BioTherapeutics, Inc. (AGLE)
Result
Sign in to run the valuation for AGLE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Aeglea BioTherapeutics, Inc. Logo Aeglea BioTherapeutics, Inc. Analysis (AGLE)

United States Health Care Official Website Stock

Is Aeglea BioTherapeutics, Inc. a good investment? Aeglea BioTherapeutics, Inc. (AGLE) is currently trading at 12.01 USD.

Investor FAQ

Does Aeglea BioTherapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aeglea BioTherapeutics, Inc.?

Aeglea BioTherapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Exchange Ticker
US SYRE
NMS (United States) AGLE
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 8, 2023 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion